EC
NBIX icon

Elequin Capital’s Neurocrine Biosciences NBIX Stock Holding History

Elequin Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-195
Closed -$19K – 631
2022
Q2 		$19K Buy
195
+19
+11% +$1.75K ﹤0.01% 197
2022
Q1 		$17K Buy
+176
New +$14.9K ﹤0.01% 131

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Elequin Capital's NBIX Position: Q3 2022 in Review

Elequin Capital sold out of Neurocrine Biosciences (NBIX) in Q3 2022, closing a stake of 195 shares — an estimated $19K sold.

Elequin Capital first reported a position in NBIX in Q1 2022 and held it in 2 quarters. The position peaked at $19K in Q2 2022. 466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • Elequin Capital reported no remaining Neurocrine Biosciences position as of Q3 2022 after selling out during the quarter.
  • Elequin Capital sold 195 Neurocrine Biosciences shares in Q3 2022, an estimated $19K.
  • Elequin Capital first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 2 quarters.
  • Elequin Capital's Neurocrine Biosciences position peaked at $19K in Q2 2022.
  • 466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Elequin Capital's 13F filing for Q3 2022, filed 10 Nov 2022.